Document Detail

Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension.
MedLine Citation:
PMID:  9926278     Owner:  NLM     Status:  MEDLINE    
Using cine magnetic resonance imaging (MRI) and echocardiography, we investigated the effects of candesartan cilexetil, a specific angiotensin II type 1 (AT1) receptor antagonist, on left ventricular (LV) mass and hemodynamics in patients with essential hypertension. Ten patients (four men and six women) with essential hypertension received candesartan cilexetil 2-8 mg/day orally for 8-12 weeks. After drug administration, systolic blood pressure (BP) decreased from 178.9 +/- 17.2 mmHg (mean +/- SD) to 150.2 +/- 14.3 mmHg (P < 0.0001) and diastolic BP from 101.4 +/- 6.5 mmHg to 87.8 +/- 11.9 mmHg (P = 0.0021). Both MRI and echocardiography revealed a significant decrease in LV mass index (LVMI) after candesartan cilexetil. MRI indicated that LVMI decreased from 111.3 +/- 31.3 g/m2 to 102.6 +/- 32.1 g/m2 (P = 0.0484) and echocardiography that LVMI decreased from 123.9 +/- 31.1 g/m2 to 115.8 +/- 31.4 g/m2 (P = 0.0316). Total systemic vascular resistance decreased significantly during treatment with candesartan cilexetil in both MRI and echocardiography assessment, from 1847.2 +/- 636.3 to 1540.4 +/- 432.0 (P = 0.0034) on MRI and from 1820.4 +/- 318.8 to 1659.0 +/- 317.7 (P = 0.0060) on echocardiography. These findings suggest that candesartan cilexetil 2-8 mg/day orally for 8-12 weeks is beneficial in the regression of cardiac hypertrophy in patients with essential hypertension.
K Mitsunami; S Inoue; K Maeda; S Endoh; M Takahashi; M Okada; H Sugihara; M Kinoshita
Related Documents :
1791878 - The microcirculation and essential hypertension.
18049028 - Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on lar...
7994448 - Hemodynamic and humoral effects of low-dose aspirin in treated and untreated essential ...
6351148 - Attention and autonomic self-regulation.
19169378 - Elevated hydrostatic pressure triggers release of opa1 and cytochrome c, and induces ap...
2938848 - Measurement of transstenotic pressure gradient during percutaneous transluminal coronar...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  12     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  1998 Oct 
Date Detail:
Created Date:  1999-03-30     Completed Date:  1999-03-30     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  469-74     Citation Subset:  IM    
First Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin Receptor Antagonists*
Antihypertensive Agents / therapeutic use*
Benzimidazoles / therapeutic use*
Biphenyl Compounds / therapeutic use*
Blood Pressure / drug effects
Hemodynamics / drug effects*
Hypertension / drug therapy*
Hypertrophy, Left Ventricular / drug therapy*
Linear Models
Magnetic Resonance Imaging
Middle Aged
Prospective Studies
Reg. No./Substance:
0/Angiotensin Receptor Antagonists; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Biphenyl Compounds; 0/Tetrazoles; R85M2X0D68/candesartan cilexetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels ...
Next Document:  Postrepolarization refractoriness as a potential anti-atrial fibrillation mechanism of pilsicainide,...